Dose-adjusted EPOCH-R plus venetoclax: a toxic bend in the road to improving R-CHOP?

Martine E. D. Chamuleau

doi:10.1016/S2352-3026(21)00282-9

Dose-adjusted EPOCH-R plus venetoclax: a toxic bend in the road to improving R-CHOP?

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Pages (from-to)	e781-e783
Journal	The Lancet Haematology
Volume	8
Issue number	11
DOIs	https://doi.org/10.1016/S2352-3026(21)00282-9
Publication status	Published - 1 Nov 2021

Access to Document

10.1016/S2352-3026(21)00282-9

Cite this

@article{f191b506cac94187b395bd594ba23548,

title = "Dose-adjusted EPOCH-R plus venetoclax: a toxic bend in the road to improving R-CHOP?",

author = "Chamuleau, {Martine E. D.}",

note = "Funding Information: MEDC reports research funding from Bristol Myers Squibb–Celgene, GenMab, and Gilead; consulting fees from AbbVie; and payment for advisory board role from Novartis.",

year = "2021",

month = nov,

day = "1",

doi = "10.1016/S2352-3026(21)00282-9",

language = "English",

volume = "8",

pages = "e781--e783",

journal = "Lancet haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "11",

}

TY - JOUR

T1 - Dose-adjusted EPOCH-R plus venetoclax

T2 - a toxic bend in the road to improving R-CHOP?

AU - Chamuleau, Martine E. D.

N1 - Funding Information: MEDC reports research funding from Bristol Myers Squibb–Celgene, GenMab, and Gilead; consulting fees from AbbVie; and payment for advisory board role from Novartis.

PY - 2021/11/1

Y1 - 2021/11/1

UR - http://www.scopus.com/inward/record.url?scp=85117819330&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(21)00282-9

DO - 10.1016/S2352-3026(21)00282-9

M3 - Comment/Letter to the editor

C2 - 34634255

VL - 8

SP - e781-e783

JO - Lancet haematology

JF - Lancet haematology

SN - 2352-3026

IS - 11

ER -

Dose-adjusted EPOCH-R plus venetoclax: a toxic bend in the road to improving R-CHOP?

Access to Document

Other files and links

Cite this